Dermata Therapeutics Inc (NASDAQ: DRMA)’s stock price has increased by 14.81 compared to its previous closing price of 1.35. However, the company has seen a 31.35% increase in its stock price over the last five trading sessions. benzinga.com reported 2025-03-27 that Dermata Therapeutics, Inc. DRMA stock is trading higher on Thursday.
Is It Worth Investing in Dermata Therapeutics Inc (NASDAQ: DRMA) Right Now?
Additionally, the 36-month beta value for DRMA is 0.49. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DRMA is 3.99M and currently, short sellers hold a 4.73% ratio of that float. The average trading volume of DRMA on March 27, 2025 was 341.05K shares.
DRMA’s Market Performance
DRMA stock saw an increase of 31.35% in the past week, with a monthly gain of 30.24% and a quarterly increase of 26.01%. The volatility ratio for the week is 8.51%, and the volatility levels for the last 30 days are 7.28% for Dermata Therapeutics Inc (DRMA). The simple moving average for the last 20 days is 26.32% for DRMA stock, with a simple moving average of -2.97% for the last 200 days.
DRMA Trading at 27.53% from the 50-Day Moving Average
After a stumble in the market that brought DRMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.75% of loss for the given period.
Volatility was left at 7.28%, however, over the last 30 days, the volatility rate increased by 8.51%, as shares surge +42.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.28% upper at present.
During the last 5 trading sessions, DRMA rose by +40.68%, which changed the moving average for the period of 200-days by -49.70% in comparison to the 20-day moving average, which settled at $1.2325. In addition, Dermata Therapeutics Inc saw 14.81% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for DRMA
The total capital return value is set at -8.02. Equity return is now at value -310.44, with -213.46 for asset returns.
Currently, EBITDA for the company is -12.51 billion with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
In conclusion, Dermata Therapeutics Inc (DRMA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
